Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.
about
Dimethyl fumarate for multiple sclerosisDimethyl fumarate for multiple sclerosisDimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapyDimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerationsComparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosisLaquinimod therapy in multiple sclerosis: a comprehensive reviewThe clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders12/15-Lipoxygenase-mediated enzymatic lipid oxidation regulates DC maturation and function.The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implicationsNew approaches to treating Alzheimer's diseaseEfficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trialsDimethyl fumarate inhibits integrin α4 expression in multiple sclerosis modelsTime course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosisEfficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis.Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.Role of the Nrf2 signaling system in health and disease.Dimethyl Fumarate: A Review in Relapsing-Remitting MS.Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.Sex Bias in Pathogenesis of Autoimmune Neuroinflammation: Relevance for Dimethyl Fumarate Immunomodulatory/Anti-oxidant Action.Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials.T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis.Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
P2860
Q24186433-C3BEBF70-9103-42BC-9A08-B21F6A3275F4Q24197602-FE32F9D6-04B7-49FF-9CF3-368B74779BEEQ26738969-531F1336-3760-4664-9221-27238912EB84Q26752859-A3978D87-0D49-4AE4-BCD1-4CA0826FCC85Q28081636-3110E72F-C168-406C-A6CD-12FA564F4824Q28086844-307C7D78-B355-471D-B8D4-0066422A230AQ28395641-5888E6B3-E194-4468-9B24-89CEF5C62D28Q30371651-AAD9190C-840B-4590-BFCF-73114CB392A8Q33621682-1E292A98-DD52-4955-A848-13DCCFF08B6BQ33970540-3E926151-DA3F-4F27-8CCE-FB94AC946867Q35081742-3639E6DF-ABB3-4B7A-BF6F-8DB59CA7EFBEQ35115898-53401D8D-0AE2-4708-88BA-7E3B9619617AQ36154808-7C0D1ABE-717F-4F03-93C4-0566ABCC87AAQ36361543-E04EB53B-4674-4783-B8A2-CF224A160EC1Q37343648-07C4C31F-DE77-4EEA-94C3-3E7EA7377B62Q38195521-A1F4708B-604A-4C03-B0F4-05B8F1CD2394Q38237494-5DA2A8A4-61C6-4187-B451-80C039FB1B2DQ38675014-A5B29872-E40F-4955-B458-3B90BB03E118Q39100528-B37B82F7-C41E-4316-A728-CB9A74B9F912Q40189763-3A82C313-DA42-4604-87F4-BC99C52CECEEQ40425312-104B59F4-EF78-4797-8789-D2A1FDD4B7B8Q41197212-458DEAFE-3F57-4DC8-98A8-B694F4FF737BQ48088068-A5BA6084-9C47-4E57-B61C-18CD83B35EB5Q58805531-42902AF9-093A-4B44-A9EA-2376BEAE75CB
P2860
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Clinical efficacy of BG-12 (di ...... analyses of the DEFINE study.
@en
type
label
Clinical efficacy of BG-12 (di ...... analyses of the DEFINE study.
@en
prefLabel
Clinical efficacy of BG-12 (di ...... analyses of the DEFINE study.
@en
P2093
P2860
P1433
P1476
Clinical efficacy of BG-12 (di ...... analyses of the DEFINE study.
@en
P2093
Amit Bar-Or
Douglas L Arnold
John O'Gorman
Katherine T Dawson
Krzysztof Selmaj
Monica Stephan
P2860
P2888
P304
P356
10.1007/S00415-013-6954-7
P577
2013-09-01T00:00:00Z